Verastem’s (VSTM) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Verastem (NASDAQ:VSTM) in a research report sent to investors on Wednesday morning,Weiss Ratings reports.

A number of other research analysts have also recently issued reports on the company. B. Riley raised Verastem to a “strong-buy” rating in a research note on Monday, August 25th. Wall Street Zen upgraded Verastem from a “sell” rating to a “hold” rating in a report on Sunday, September 21st. Zacks Research upgraded Verastem to a “hold” rating in a report on Tuesday, August 12th. Royal Bank Of Canada boosted their price target on Verastem from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Finally, BTIG Research restated a “buy” rating and issued a $20.00 price target on shares of Verastem in a report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $13.29.

Verastem Stock Down 7.3%

NASDAQ:VSTM opened at $8.57 on Wednesday. Verastem has a 1 year low of $2.54 and a 1 year high of $11.24. The company has a current ratio of 3.46, a quick ratio of 3.44 and a debt-to-equity ratio of 2.06. The stock has a market cap of $527.40 million, a price-to-earnings ratio of -2.61 and a beta of 0.89. The stock has a 50-day moving average price of $8.71 and a two-hundred day moving average price of $6.92.

Verastem (NASDAQ:VSTM) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.25. The business had revenue of $2.14 million during the quarter, compared to analyst estimates of $6.01 million. As a group, equities analysts expect that Verastem will post -3.02 earnings per share for the current year.

Institutional Trading of Verastem

Institutional investors and hedge funds have recently bought and sold shares of the stock. E Fund Management Co. Ltd. bought a new stake in Verastem during the second quarter worth about $49,000. Nebula Research & Development LLC bought a new stake in Verastem during the second quarter worth about $53,000. The Manufacturers Life Insurance Company raised its holdings in Verastem by 9.8% during the second quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 1,440 shares in the last quarter. Profund Advisors LLC bought a new stake in Verastem during the second quarter worth about $90,000. Finally, Los Angeles Capital Management LLC bought a new stake in Verastem during the second quarter worth about $106,000. Institutional investors own 88.37% of the company’s stock.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.